Table 1 Baseline patient characteristics and treatment
|  |  | Patients (N = 208) | n |
|---|---|---|---|
Age (y/o) | Median 69 (48–90) |  |  |
|  | Age ≤ 60 | 12.5% | 26 |
|  | 60 < Age ≤ 70 | 46.2% | 96 |
|  | Age > 70 | 41.3% | 86 |
Race | White | 54.8% | 114 |
| Â | Black | 38.0% | 79 |
| Â | Other | 7.2% | 15 |
Charlson Comorbidity Index | CCI = 0 | 68.3% | 142 |
|  | CCI = 1 | 22.6% | 47 |
|  | CCI ≥ 2 | 9.1% | 19 |
Body Mass Index (BMI) | Median 27.34 (15.02-44.96) | Â | Â |
|  | BMI ≥ 30 | 29.3% | 61 |
Partner Status | Married or Partnered | 76.4% | 159 |
| Â | Not Partnered | 23.6% | 49 |
Employment Status | Working | 47.6% | 99 |
| Â | Not Working | 52.4% | 109 |
Median Prostate Volume (cc) | Median 38.6 (11.6-138.7) cc | Â | 208 |
Baseline AUA Score | Median 7 (0 – 34) |  | 141 |
Procedure for BPH | Â | 11.5% | 24 |
α 1A inhibitor usage |  | 27.4% | 57 |
Anticoagulant usage | Â | 32.2% | 67 |
Risk Groups (D’Amico’s) | Low | 39.4% | 82 |
| Â | Intermediate | 52.4% | 109 |
| Â | High | 8.2% | 17 |
ADT | Â | 14.4% | 30 |
SBRT Dose | 36.25Â Gy | 87.5% | 182 |
| Â | 35Â Gy | 12.5% | 26 |